OCS Company Profile and Key Details

Q: Who are the executives of OCS?

Dr. Fang LiSenior Vice President of Regulatory AffairsDr. Riad Sherif M.B.A., M.D.Chief Executive Officer & DirectorDr. Joanne Chang M.D., Ph.D.Head of Medical Affairs & Chief Medical OfficerMs. Sylvia CheungChief Financial OfficerMr. Weibo DingGlobal Chief Operating Officer & GM of ChinaDr. Bastian DehmelChief Devel. Officer & Head of Devel.Mr. Páll Ragnar JóhannessonChief Strategy Officer

NASDAQ : OCS

Oculis Holding AG

$20.35

-0.9-4.24%

At Close 4:00 PM

Profile Key Stats Analyst Ratings Ownership Ratios Financials Dividend & splits Sentiment Forecast

Price Chart

Stock Price Today

Oculis Holding AG (OCS) stock surged +0.64%, trading at $20.48 on NASDAQ, up from the previous close of $20.35. The stock opened at $20.65, fluctuating between $20.40 and $20.84 in the recent session.

Stock Snapshot

20.35

Prev. Close

1.07B

Market Cap

20.4

Day Low

-7.53

P/E Ratio

-2.72

EPS (TTM)

-1.47

Cash Flow per Share

20.65

Open

52.37M

Number of Shares

20.84

Day High

70.51%

Free Float in %

2.55

Book Value

99.1K

Volume

Relevant Articles

SEC Fillings

Current Report (8-k)

Filing Date	Accepted Date

Annual Report (10-k)

Filing Date	Accepted Date

Stock Price History Chart

Date	Open	High	Low	Close	Volume
Dec 22, 2025	21.32	21.33	20.18	20.35	174.45K
Dec 19, 2025	20.75	21.33	20.50	21.25	411.33K
Dec 17, 2025	19.84	19.86	19.12	19.43	128.75K
Dec 16, 2025	20.51	20.59	19.71	19.84	136.06K
Dec 15, 2025	20.71	20.97	20.42	20.47	98.08K
Dec 12, 2025	20.90	21.00	20.54	20.73	91.8K
Dec 11, 2025	20.63	21.00	20.45	20.88	48.94K
Dec 10, 2025	20.63	20.76	20.41	20.63	17.32K
Dec 09, 2025	20.50	20.69	20.40	20.52	29.4K
Dec 08, 2025	21.82	21.86	20.10	20.59	94.92K
Dec 05, 2025	19.81	21.68	19.81	21.68	213.59K
Dec 04, 2025	18.98	19.84	18.98	19.70	92.59K
Dec 03, 2025	18.93	19.03	18.71	18.99	44.96K
Dec 02, 2025	19.06	19.06	18.65	18.79	94.24K
Dec 01, 2025	19.02	19.10	18.82	19.00	134.87K
Nov 28, 2025	18.91	19.05	18.83	19.00	100.85K
Nov 26, 2025	19.46	19.61	18.76	18.91	62.65K
Nov 25, 2025	19.42	19.45	19.25	19.33	122.81K
Nov 24, 2025	19.40	19.40	19.16	19.29	102.92K
Nov 21, 2025	19.22	19.31	19.07	19.26	100.37K

Contact Details

Zug, 6300

Switzerland

https://oculis.com 415 881 00182

About Company

Oculis Holding AG, a clinical-stage biopharmaceutical company, develops novel topical treatments for ophthalmic diseases for both back- and front-of-the-eye. The company's lead candidate is OCS-01, a topical dexamethasone formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for keratoconjunctivitis sicca, or dry eye disease; and OCS-05, a novel neuroprotective agent for acute optic neuritis and other neuro-ophtha disorders, such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. The company is based in Zug, Switzerland.

Stock Peers

ARGX

-2.95-0.35%

argenx SE$852.04 REGN

11.4+1.48%

Regeneron Pharmaceuticals, Inc.$779.36 MDGL

11.81+2.00%

Madrigal Pharmaceuticals, Inc.$602.83 UTHR

-3.34-0.65%

United Therapeutics Corporation$513.79 VRTX

4.11+0.90%

Vertex Pharmaceuticals Incorporated$460.31 ALNY

7.5+1.87%

Alnylam Pharmaceuticals, Inc.$407.73 KRTX

0.09+0.03%

Karuna Therapeutics, Inc.$329.83 PRAX

7.48+2.74%

Praxis Precision Medicines, Inc.$280.40 KRYS

8.81+3.66%

Krystal Biotech, Inc.$249.61 SGEN

-0.16-0.07%

Seagen Inc.$228.74

Company Overview

Oculis Holding AG (NASDAQ:OCS) closed at $20.48 USD, gaining $0.13 (0.64%) from the previous close of $20.35. The stock is currently mid-range between its 52-week high and low $14.00 and $23.08. With a market capitalization of about $1.07 billion, Oculis Holding AG is classified as a small-cap and shows lower-than-market volatility (beta ~0.14). Key stats such as the average daily volume over the past year has been around 105.21 thousand shares, in line with its 52-week average. Headquartered in Zug, None, Oculis Holding AG operates in the Healthcare sector and the Biotechnology industry. Led by CEO Riad Sherif, the company employs approximately 49 people and listed since May 18, 2021. Oculis Holding AG, a clinical-stage biopharmaceutical company, develops novel topical treatments for ophthalmic diseases for both back- and front-of-the-eye.

Technical Performance

Short-term trend indicators are mixed aligned (SMA20 2.04%, SMA50 1.09%, SMA200 8.91%). The stock’s 14-day RSI is 52.88 (neutral), while the ATR of 0.74 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -11.83% below its high and over 45.36% above its low. Average 10-day trading volume of 189.74 thousand shares is significantly above the 3-month average of 101.00 thousand, indicating heightened recent market interest.

Valuation Metrics

Oculis Holding AG trades at a P/E ratio of -7.89, slightly below the S&P 500 average, with a price-to-sales ratio of 3254.37 and a price-to-book ratio of 5.93 trading at moderately above to book value. The P/FCF stands at -14.54, also below market averages.

Dividend & Fair Value

Oculis Holding AG last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $1.22. This means the shares are trading above this model’s fair value.

Earnings & Analyst Outlook

Wall Street analysts project EPS growth of 4.59% annually over the next five years. The latest quarter delivered EPS of -$0.40. The next quarter is forecast at -$0.51. Next year's EPS is expected at $49.94. Analyst sentiment is bullish. Analyst rating data shows there are 3 Strong Buy ratings, 13 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $55.00 to $28.00. The high target offers 170.27% upside. The low target suggests 37.59% downside. The mean target is $37.69. This offers 85.21% upside. Oculis Holding AG earnings surprise history is a consistent trend of beating forecasts. The quarter that ended November 10, 2025, missed forecasts by -19.65%. The prior quarter beat by 11.32%. Over the last six quarters, Apple has recorded several small beats. These include 30.23% in August 27, 2024.

Shareholding & Insider Activity

Oculis Holding AG has 51.03 million shares outstanding. The public float is 41.38 million shares, elevated short interest at 0.02% of float. This equals 9.62 thousand shares. The short ratio is 0.64 days. Institutional investors hold 33.32% of the float. Insiders own 6.31%.

Financial & Profitability Overview

Over the trailing twelve months, Oculis Holding AG generated $883.00K in revenue, or $0.03 per share. Gross margin was -3212.23%, operating margin -5192.64%, and net profit margin -10056.85%. Returns are negative, with ROA at -77.66% and ROE at -94.74%.
On valuation metrics, Oculis Holding AG trades at a P/E of -7.89, P/S of 3254.37 and P/B of 5.93. The current ratio is 4.55 and quick ratio is 4.55. Operationally, the company’s inventory turnover is 0.00 and cash conversion cycle is 3393.97 days. Debt-to-equity is 0.01, supported by a cash flow-to-debt ratio of -55.33.

Quarterly Financial Highlights

For the quarter ended Dec 31, 2023, Oculis Holding AG posted revenue of $883.00K, down slightly from $0.00 in the prior quarter. Gross profit was - $28.36M (margin -3212.23%). Operating income was - $45.85M (margin -5192.6%). Net income was- $88.80M (EPS - $2.97).
The company ended the quarter with $91.65M in cash and short-term investments, a total debt of $605.00K, and net debt of - $37.72M. Total assets were $114.35M, with equity of $93.73M. Financials further reflected weakness, with operating cash flow of - $53.85M, free cash flow of - $53.89M, and capital expenditures of - $48.00K.

Price Forecast & Outlook

Our AI price prediction model suggests that Oculis Holding AG stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 5.31%, with price expected at $21.43 by January 05, 2026, within a range of $20.86 to $22.02 3-Month Outlook: Projected rise of 4.82%, reaching $21.33 by March 20, 2026, with a range of $21.07 to $21.64. 1-Year Outlook: Projected gain of 18.28%, with price at $24.07 by December 22, 2026, within a range of $23.38 to $24.79.

Key Takeaways

Oculis Holding AG (NASDAQ:OCS) shares are up 19.71% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows Oculis Holding AG trading at a premium to the broader market with a P/E of -7.89. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $34.85, suggesting 71.25% upside. Our AI forecast model points to short-term strength (5.31% over two weeks), a medium-term rise (4.82% over three months), and a longer-term gain (18.28% over one year), with expected trading ranges indicating moderate volatility.

Frequently Asked Questions

What is the current Oculis Holding AG (OCS) stock price?

Oculis Holding AG (NASDAQ: OCS) stock price is $20.48 in the last trading session. During the trading session, OCS stock reached the peak price of $20.84 while $20.40 was the lowest point it dropped to. The percentage change in OCS stock occurred in the recent session was 0.64% while the dollar amount for the price change in OCS stock was $0.13.

OCS's industry and sector of operation?

The NASDAQ listed OCS is part of Biotechnology industry that operates in the broader Healthcare sector. Oculis Holding AG designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.

Who are the executives of OCS?

Dr. Fang Li
Senior Vice President of Regulatory Affairs
Dr. Riad Sherif M.B.A., M.D.
Chief Executive Officer & Director
Dr. Joanne Chang M.D., Ph.D.
Head of Medical Affairs & Chief Medical Officer
Ms. Sylvia Cheung
Chief Financial Officer
Mr. Weibo Ding
Global Chief Operating Officer & GM of China
Dr. Bastian Dehmel
Chief Devel. Officer & Head of Devel.
Mr. Páll Ragnar Jóhannesson
Chief Strategy Officer

How OCS did perform over past 52-week?

OCS's closing price is 45.36% higher than its 52-week low of $14.00 where as its distance from 52-week high of $23.08 is -11.83%.

How many employees does OCS have?

Number of OCS employees currently stands at 49.

Link for OCS official website?

Official Website of OCS is: https://oculis.com

How do I contact OCS?

OCS could be contacted at phone 415 881 00182 and can also be accessed through its website. OCS operates from Bahnhofstrasse 7, Zug, 6300, Switzerland.

How many shares of OCS are traded daily?

OCS stock volume for the day was 99.1K shares. The average number of OCS shares traded daily for last 3 months was 105.21K.

What is the market cap of OCS currently?

The market value of OCS currently stands at $1.07B with its latest stock price at $20.48 and 52.37M of its shares outstanding.

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

Employees	49
Beta	0.14
Sales or Revenue	$883.00K
5Y Sales Change%	-0.026%
Fiscal Year Ends	December
Sector	Healthcare
Industry	Biotechnology

OCS Company Profile and Key Details

Oculis Holding AG

Price Chart

Stock Price Today

Stock Snapshot

Relevant Articles

SEC Fillings

Current Report (8-k)

Annual Report (10-k)

Stock Price History Chart

Contact Details

About Company

Company Information

Stock Peers

Company Overview

Technical Performance

Valuation Metrics

Dividend & Fair Value

Earnings & Analyst Outlook

Shareholding & Insider Activity

Financial & Profitability Overview

Quarterly Financial Highlights

Price Forecast & Outlook

Key Takeaways

Frequently Asked Questions

Technical Performance

Dividend & Fair Value

Earnings & Analyst Outlook

Financial & Profitability Overview

Quarterly Financial Highlights

Key Takeaways

Price Forecast & Outlook

Valuation Metrics